Evaluation of a new bladder tumor marker.
Two monoclonal antibodies have been developed that bind to a shed bladder tumor-associated antigen. Preliminary data have demonstrated that antigen-positive tumors shed detectable amounts of antigen in the urine while antigen-negative tumors do not. This antigen may be differentially metabolized by normal and malignant urothelial cells. Further characterization of this antigen and its evaluation as a urinary marker for antigen positive bladder cancers is continuing.
Grossman
H B
HB
Department of Surgery, University of Michigan, Ann Arbor.
Liebert
M
M
Sakakibara
N
N
Wedemeyer
G A
GA
Stein
J A
JA
Washington
R W
RW
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D015153:Blotting, Western; D006383:Hemadsorption Inhibition Tests; D006801:Humans; D007124:Immunoenzyme Techniques; D008970:Molecular Weight; D011863:Radioimmunoassay; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor